Search

Your search keyword '"McQuade, Jennifer L."' showing total 330 results
Start Over Author "McQuade, Jennifer L."
330 results on '"McQuade, Jennifer L."'

3. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab

Author

Starling, Caroline T, Messer, Alison A, Kleiman, Anne, McQuade, Jennifer L, Glitza, Isabella C, Torres-Cabala, Carlos Antonio, and Heberton, Meghan

Subjects
granulomatous dermatitis, immunotherapy, interstitial, melanoma
Abstract

Immune-related adverse events (irAEs) are common in patients receiving immune checkpoint inhibitors for metastatic melanoma and other advanced malignancies. Cutaneous, gastrointestinal, and endocrine (thyroid) irAEs are most prevalent, whereas neurologic irAEs are rare. We present a 73-year-old man with dementia and metastatic melanoma who developed immunotherapy-associated encephalitis and subsequently, interstitial granulomatous dermatitis with nivolumab/ipilimumab. High-dose corticosteroids successfully treated both conditions, though he never regained his baseline mental status. We review the literature on interstitial granulomatous dermatitis and encephalitis with immunotherapy.

Published
2022

4. Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Author

Glitza Oliva, Isabella C., Ferguson, Sherise D., Bassett, Jr, Roland, Foster, Alexandra P., John, Ida, Hennegan, Tarin D., Rohlfs, Michelle, Richard, Jessie, Iqbal, Masood, Dett, Tina, Lacey, Carol, Jackson, Natalie, Rodgers, Theresa, Phillips, Suzanne, Duncan, Sheila, Haydu, Lauren, Lin, Ruitao, Amaria, Rodabe N., Wong, Michael K., Diab, Adi, Yee, Cassian, Patel, Sapna P., McQuade, Jennifer L., Fischer, Grant M., McCutcheon, Ian E., O’Brien, Barbara J., Tummala, Sudhakar, Debnam, Matthew, Guha-Thakurta, Nandita, Wargo, Jennifer A., Carapeto, Fernando C. L., Hudgens, Courtney W., Huse, Jason T., Tetzlaff, Michael T., Burton, Elizabeth M., Tawbi, Hussein A., and Davies, Michael A.

Published
2024
Full Text
View/download PDF

5. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Author

Glitza Oliva, Isabella C., Ferguson, Sherise D., Bassett, Jr, Roland, Foster, Alexandra P., John, Ida, Hennegan, Tarin D., Rohlfs, Michelle, Richard, Jessie, Iqbal, Masood, Dett, Tina, Lacey, Carol, Jackson, Natalie, Rodgers, Theresa, Phillips, Suzanne, Duncan, Sheila, Haydu, Lauren, Lin, Ruitao, Amaria, Rodabe N., Wong, Michael K., Diab, Adi, Yee, Cassian, Patel, Sapna P., McQuade, Jennifer L., Fischer, Grant M., McCutcheon, Ian E., O’Brien, Barbara J., Tummala, Sudhakar, Debnam, Matthew, Guha-Thakurta, Nandita, Wargo, Jennifer A., Carapeto, Fernando C. L., Hudgens, Courtney W., Huse, Jason T., Tetzlaff, Michael T., Burton, Elizabeth M., Tawbi, Hussein A., and Davies, Michael A.

Published
2023
Full Text
View/download PDF

6. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial

Author

Zhang, Xiaotao, Irajizad, Ehsan, Hoffman, Kristi L., Fahrmann, Johannes F., Li, Fangyu, Seo, Yongwoo David, Browman, Gladys J., Dennison, Jennifer B., Vykoukal, Jody, Luna, Pamela N., Siu, Wesley, Wu, Ranran, Murage, Eunice, Ajami, Nadim J., McQuade, Jennifer L., Wargo, Jennifer A., Long, James P., Do, Kim-Anh, Lampe, Johanna W., Basen-Engquist, Karen M., Okhuysen, Pablo C., Kopetz, Scott, Hanash, Samir M., Petrosino, Joseph F., Scheet, Paul, and Daniel, Carrie R.

Published
2023
Full Text
View/download PDF

8. Neoadjuvant relatlimab and nivolumab in resectable melanoma

Author

Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tezlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, and Tawbi, Hussein A.

Published
2022
Full Text
View/download PDF

11. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2022
Full Text
View/download PDF

12. Body composition in recurrent prostate cancer and the role of steroidogenic genotype.

Author

Venkatesh, Neha, Tidwell, Rebecca S., Yao Yu, Aparicio, Ana, Zurita, Amado J., Subudhi, Sumit K., Siddiqui, Bilal A., Mukhida, Sagar S., Gregg, Justin R., Corn, Paul G., Koutroumpakis, Efstratios, McQuade, Jennifer L., Frigo, Daniel E., Pilie, Patrick G., Huff, Chad, Logothetis, Christopher J., and Hahn, Andrew W.

Abstract

Hormone therapy (HT) to treat prostate cancer is reported to cause adverse changes in body composition. Clinically, interpatient body composition changes are heterogeneous, but the biological and clinical determinants of body composition toxicity are unknown. Herein, we test the hypothesis that inherited polymorphisms in steroidogenic genes are associated with differential changes in body composition after HT. Men with biochemically recurrent prostate cancer (BCR) who received 8 months of LHRH analog (LHRHa) +/- abiraterone acetate (AAP) were eligible if they had: i) CT imaging of L3 prior to and after treatment; and ii) nucleated cells collected. Cardiometabolic co-morbidities were retrospectively extracted. Body composition was measured using an AI-based segmentation tool. Germline DNA whole exome or genome sequencing was performed. In 162 men treated with 8 months of HT, median skeletal muscle mass (SMMi) loss was 6.6% and subcutaneous adipose gain was 12.3%. Men with type 2 diabetes had higher losses of SMMi after treatment (-11.1% vs -6.3%, P = 0.003). For the 150 men with germline NGS, SRD5A2 rs523349 genotype was associated with differential loss in skeletal muscle density after HT, (-1.3% vs -7.1%, P = 0.04). In addition, the HSD3B1 rs104703 genotype was associated with decreased baseline visceral adipose tissue (63.0 cm2/m2 vs 77.9, P = 0.05). In men with BCR, HT induced notable loss of skeletal muscle and increased subcutaneous adipose tissue. An inherited polymorphism in SRD5A2 and T2DM was associated with differential skeletal muscle toxicity. These findings suggest that inherited polymorphisms may contribute to the body composition toxicity observed with HT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations

Author

Kugel, Curtis H, Douglass, Stephen M, Webster, Marie R, Kaur, Amanpreet, Liu, Qin, Yin, Xiangfan, Weiss, Sarah A, Darvishian, Farbod, Al-Rohil, Rami N, Ndoye, Abibatou, Behera, Reeti, Alicea, Gretchen M, Ecker, Brett L, Fane, Mitchell, Allegrezza, Michael J, Svoronos, Nikolaos, Kumar, Vinit, Wang, Daniel Y, Somasundaram, Rajasekharan, Hu-Lieskovan, Siwen, Ozgun, Alpaslan, Herlyn, Meenhard, Conejo-Garcia, Jose R, Gabrilovich, Dmitry, Stone, Erica L, Nowicki, Theodore S, Sosman, Jeffrey, Rai, Rajat, Carlino, Matteo S, Long, Georgina V, Marais, Richard, Ribas, Antoni, Eroglu, Zeynep, Davies, Michael A, Schilling, Bastian, Schadendorf, Dirk, Xu, Wei, Amaravadi, Ravi K, Menzies, Alexander M, McQuade, Jennifer L, Johnson, Douglas B, Osman, Iman, and Weeraratna, Ashani T

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Vaccine Related, Immunization, Aging, 2.1 Biological and endogenous factors, Aetiology, Age Factors, Animals, Antineoplastic Agents, Immunological, Biomarkers, Tumor, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Disease Models, Animal, Female, Humans, Immunomodulation, Melanoma, Mice, Mice, Transgenic, Neoplasms, Programmed Cell Death 1 Receptor, T-Lymphocytes, Regulatory, Tumor Microenvironment, Xenograft Model Antitumor Assays, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

Purpose: We have shown that the aged microenvironment increases melanoma metastasis, and decreases response to targeted therapy, and here we queried response to anti-PD1.Experimental Design: We analyzed the relationship between age, response to anti-PD1, and prior therapy in 538 patients. We used mouse models of melanoma, to analyze the intratumoral immune microenvironment in young versus aged mice and confirmed our findings in human melanoma biopsies.Results: Patients over the age of 60 responded more efficiently to anti-PD-1, and likelihood of response to anti-PD-1 increased with age, even when we controlled for prior MAPKi therapy. Placing genetically identical tumors in aged mice (52 weeks) significantly increased their response to anti-PD1 as compared with the same tumors in young mice (8 weeks). These data suggest that this increased response in aged patients occurs even in the absence of a more complex mutational landscape. Next, we found that young mice had a significantly higher population of regulatory T cells (Tregs), skewing the CD8+:Treg ratio. FOXP3 staining of human melanoma biopsies revealed similar increases in Tregs in young patients. Depletion of Tregs using anti-CD25 increased the response to anti-PD1 in young mice.Conclusions: While there are obvious limitations to our study, including our inability to conduct a meta-analysis due to a lack of available data, and our inability to control for mutational burden, there is a remarkable consistency in these data from over 500 patients across 8 different institutes worldwide. These results stress the importance of considering age as a factor for immunotherapy response. Clin Cancer Res; 24(21); 5347-56. ©2018 AACR See related commentary by Pawelec, p. 5193.

Published
2018

14. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Author

McQuade, Jennifer L, Daniel, Carrie R, Hess, Kenneth R, Mak, Carmen, Wang, Daniel Y, Rai, Rajat R, Park, John J, Haydu, Lauren E, Spencer, Christine, Wongchenko, Matthew, Lane, Stephen, Lee, Dung-Yang, Kaper, Mathilde, McKean, Meredith, Beckermann, Kathryn E, Rubinstein, Samuel M, Rooney, Isabelle, Musib, Luna, Budha, Nageshwar, Hsu, Jessie, Nowicki, Theodore S, Avila, Alexandre, Haas, Tomas, Puligandla, Maneka, Lee, Sandra, Fang, Shenying, Wargo, Jennifer A, Gershenwald, Jeffrey E, Lee, Jeffrey E, Hwu, Patrick, Chapman, Paul B, Sosman, Jeffrey A, Schadendorf, Dirk, Grob, Jean-Jacques, Flaherty, Keith T, Walker, Dana, Yan, Yibing, McKenna, Edward, Legos, Jeffrey J, Carlino, Matteo S, Ribas, Antoni, Kirkwood, John M, Long, Georgina V, Johnson, Douglas B, Menzies, Alexander M, and Davies, Michael A

Subjects
Clinical Research, Obesity, Cancer, Clinical Trials and Supportive Activities, Nutrition, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Body Mass Index, Female, Humans, Male, Melanoma, Middle Aged, Molecular Targeted Therapy, Progression-Free Survival, Protective Factors, Randomized Controlled Trials as Topic, Retrospective Studies, Risk Assessment, Risk Factors, Skin Neoplasms, Time Factors, Treatment Outcome, Young Adult, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundObesity has been linked to increased mortality in several cancer types; however, the relation between obesity and survival outcomes in metastatic melanoma is unknown. The aim of this study was to examine the association between body-mass index (BMI) and progression-free survival or overall survival in patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.MethodsThis retrospective study analysed independent cohorts of patients with metastatic melanoma assigned to treatment with targeted therapy, immunotherapy, or chemotherapy in randomised clinical trials and one retrospective study of patients treated with immunotherapy. Patients were classified according to BMI, following the WHO definitions, as underweight, normal, overweight, or obese. Patients without BMI and underweight patients were excluded. The primary outcomes were the associations between BMI and progression-free survival or overall survival, stratified by treatment type and sex. We did multivariable analyses in the independent cohorts, and combined adjusted hazard ratios in a mixed-effects meta-analysis to provide a precise estimate of the association between BMI and survival outcomes; heterogeneity was assessed with meta-regression analyses. Analyses were done on the predefined intention-to-treat population in the randomised controlled trials and on all patients included in the retrospective study.FindingsThe six cohorts consisted of a total of 2046 patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy between Aug 8, 2006, and Jan 15, 2016. 1918 patients were included in the analysis. Two cohorts containing patients from randomised controlled trials treated with targeted therapy (dabrafenib plus trametinib [n=599] and vemurafenib plus cobimetinib [n=240]), two cohorts containing patients treated with immunotherapy (one randomised controlled trial of ipilimumab plus dacarbazine [n=207] and a retrospective cohort treated with pembrolizumab, nivolumab, or atezolizumab [n=331]), and two cohorts containing patients treated with chemotherapy (two randomised controlled trials of dacarbazine [n=320 and n=221]) were classified according to BMI as normal (694 [36%] patients), overweight (711 [37%]), or obese (513 [27%]). In the pooled analysis, obesity, compared with normal BMI, was associated with improved survival in patients with metastatic melanoma (average adjusted hazard ratio [HR] 0·77 [95% CI 0·66-0·90] for progression-free survival and 0·74 [0·58-0·95] for overall survival). The survival benefit associated with obesity was restricted to patients treated with targeted therapy (HR 0·72 [0·57-0·91] for progression-free survival and 0·60 [0·45-0·79] for overall survival) and immunotherapy (HR 0·75 [0·56-1·00] and 0·64 [0·47-0·86]). No associations were observed with chemotherapy (HR 0·87 [0·65-1·17, pinteraction=0·61] for progression-free survival and 1·03 [0·80-1·34, pinteraction=0·01] for overall survival). The association of BMI with overall survival for patients treated with targeted and immune therapies differed by sex, with inverse associations in men (HR 0·53 [0·40-0·70]), but no associations observed in women (HR 0·85 [0·61-1·18, pinteraction=0·03]).InterpretationOur results suggest that in patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy. These results have implications for the design of future clinical trials for patients with metastatic melanoma and the magnitude of the benefit found supports further investigation of the underlying mechanism of these associations.FundingASCO/CCF Young Investigator Award, ASCO/CCF Career Development Award, MD Anderson Cancer Center (MDACC) Melanoma Moonshot Program, MDACC Melanoma SPORE, and the Dr Miriam and Sheldon G Adelson Medical Research Foundation.

Published
2018

15. The Effect of Immune Checkpoint Inhibitor Therapy on Pre-Existing Gastroparesis and New Onset of Symptoms of Delayed Gastric Emptying.

Author

Urias Rivera, Andres C., Pizuorno Machado, Antonio, Shatila, Malek, Triadafilopoulos, George, McQuade, Jennifer L., Altan, Mehmet, Zhao, Dan, Wang, Yinghong, and Shafi, Mehnaz A.

Subjects
GASTROINTESTINAL motility, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, IMMUNE checkpoint inhibitors, DUMPING syndrome, GASTROPARESIS, DISEASE progression, SYMPTOMS
Abstract

Simple Summary: Immune checkpoint inhibitors (ICIs) offer improved outcomes for patients with various malignancies but they have also been associated with immune-related adverse events. Gastroparesis, a gastrointestinal (GI) motility disorder characterized by delayed gastric emptying (GE) and upper GI symptoms, has been linked to ICIs through histological studies indicating myenteric plexopathy. The aim of our retrospective study was to evaluate the prevalence, clinical course, and treatment for both patients with pre-existing gastroparesis and those with new symptoms of delayed GE after ICI. We found 39 patients with new delayed GE post-ICI (prevalence of 0.2%) and 37 with pre-existing gastroparesis, of which only 4 (11%) had a flare of symptoms post-ICI. We found that delayed GE post-ICI therapy is rare but with late onset and prolonged duration. The presence of alternative etiology of gastroparesis did not affect patients' duration of delayed GE symptoms or overall survival. Immune checkpoint inhibitors (ICIs) can cause myenteric plexopathy, which could result in delayed gastric emptying (GE) and possibly gastroparesis. We assessed the clinical outcomes of patients who had pre-existing gastroparesis or who developed symptoms of delayed GE following ICI therapy. We retrospectively identified adults with ICD-9 and ICD-10 codes for gastroparesis who received ICI therapy between 1 January 2020 and 31 December 2022 at a tertiary cancer center. Of 76 eligible patients, 37 had pre-existing gastroparesis; 39 (0.2% of the more than 18,000 screened) developed symptoms of delayed GE after ICI therapy, of which 27 (69%) patients had an alternative etiology for delayed GE. Four patients (11%) with pre-existing gastroparesis had a flare-up after ICI, and the median time to flare-up was 10.2 months (IQR, 0.7–28.6 months); for patients with new onset of suspected delayed GE after ICI, the median time to symptom onset was 12.8 months (IQR, 4.4–35.5 months). The clinical symptom duration of patients without an alternative etiology (74.5 days (IQR, 21.5–690 days)) and those with an alternative etiology (290 days (IQR, 147–387 days)) did not differ significantly (p = 1.00). Delayed GE after ICI therapy is a rare presentation but has a late onset and a prolonged symptom duration. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Author

Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tetzlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, and Tawbi, Hussein A.

Published
2023
Full Text
View/download PDF

17. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Author

Vellano, Christopher P., White, Michael G., Andrews, Miles C., Chelvanambi, Manoj, Witt, Russell G., Daniele, Joseph R., Titus, Mark, McQuade, Jennifer L., Conforti, Fabio, Burton, Elizabeth M., Lastrapes, Matthew J., Ologun, Gabriel, Cogdill, Alexandria P., Morad, Golnaz, Prieto, Peter, Lazar, Alexander J., Chu, Yanshuo, Han, Guangchun, Khan, M. A. Wadud, Helmink, Beth, Davies, Michael A., Amaria, Rodabe N., Kovacs, Jeffrey J., Woodman, Scott E., Patel, Sapna, Hwu, Patrick, Peoples, Michael, Lee, Jeffrey E., Cooper, Zachary A., Zhu, Haifeng, Gao, Guang, Banerjee, Hiya, Lau, Mike, Gershenwald, Jeffrey E., Lucci, Anthony, Keung, Emily Z., Ross, Merrick I., Pala, Laura, Pagan, Eleonora, Segura, Rossana Lazcano, Liu, Qian, Borthwick, Mikayla S., Lau, Eric, Yates, Melinda S., Westin, Shannon N., Wani, Khalida, Tetzlaff, Michael T., Haydu, Lauren E., Mahendra, Mikhila, Ma, XiaoYan, Logothetis, Christopher, Kulstad, Zachary, Johnson, Sarah, Hudgens, Courtney W., Feng, Ningping, Federico, Lorenzo, Long, Georgina V., Futreal, P. Andrew, Arur, Swathi, Tawbi, Hussein A., Moran, Amy E., Wang, Linghua, Heffernan, Timothy P., Marszalek, Joseph R., and Wargo, Jennifer A.

Published
2023
Full Text
View/download PDF

18. Impact of COVID-19-related experiences on health-related quality of life in cancer survivors in the United States

Author

Otto, Amy K., primary, Prinsloo, Sarah, additional, Natori, Akina, additional, Wagner, Richard W., additional, Gomez, Telma I., additional, Ochoa, Jewel M., additional, Tworoger, Shelley S., additional, Ulrich, Cornelia M., additional, Ahmed, Sairah, additional, McQuade, Jennifer L, additional, Peoples, Anita R., additional, Antoni, Michael H., additional, Bower, Julienne E., additional, Cohen, Lorenzo, additional, and Penedo, Frank J., additional

Published
2024
Full Text
View/download PDF

19. Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Author

Fayle, Sarah E., primary, Palaskas, Nicolas L., additional, Siddiqui, Bilal A., additional, McQuade, Jennifer L., additional, Lin, Jamie S., additional, Subudhi, Sumit K., additional, Patel, Anisha B., additional, Jenq, Robert R., additional, Shah, Amishi Y., additional, Spelman, Amy R., additional, Sun, Mianen, additional, Marble, Bettina H., additional, and Wang, Yinghong, additional

Published
2024
Full Text
View/download PDF

22. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Author

Andrews, Miles C, Berry, Donald A, Block, Matthew S, Boland, Genevieve M, Bollin, Kathryn B, Carlino, Matteo S, Carvajal, Richard D, Cohen, Jonathan, Davar, Diwakar, Delman, Keith A, Dummer, Reinhard, Farwell, Michael D, Fisher, David E, Fusi, Alberto, Glitza, Isabella C, de Gruijl, Tanja D, Gyorki, David E, Hauschild, Axel, Hieken, Tina J, Larkin, James, Lawson, David H, Lebbe, Celeste, Lee, Jeffrey E, Lowe, Michael C, Luke, Jason J, McArthur, Grant A, McDermott, David F, McQuade, Jennifer L, Mitchell, Tara C, Petrella, Teresa M, Prieto, Peter A, Puzanov, Igor, Robert, Caroline, Salama, April K, Sandhu, Shaneen, Schadendorf, Dirk, Shoushtari, Alexander N, Sosman, Jeffrey A, Swetter, Susan M, Tanabe, Ken K, Turajlic, Samra, Tyler, Douglas S, Woodman, Scott E, Wright, Frances C, Zager, Jonathan S, Amaria, Rodabe N, Menzies, Alexander M, Burton, Elizabeth M, Scolyer, Richard A, Tetzlaff, Michael T, Antdbacka, Robert, Ariyan, Charlotte, Bassett, Roland, Carter, Brett, Daud, Adil, Faries, Mark, Fecher, Leslie A, Flaherty, Keith T, Gershenwald, Jeffrey E, Hamid, Omid, Hong, Angela, Kirkwood, John M, Lo, Serigne, Margolin, Kim, Messina, Jane, Postow, Michael A, Rizos, Helen, Ross, Merrick I, Rozeman, Elisa A, Saw, Robyn P M, Sondak, Vernon, Sullivan, Ryan J, Taube, Janis M, Thompson, John F, van de Wiel, Bart A, Eggermont, Alexander M, Davies, Michael A, Ascierto, Paolo A, Spillane, Andrew J, van Akkooi, Alexander C J, Wargo, Jennifer A, Blank, Christian U, Tawbi, Hussein A, and Long, Georgina V

Published
2019
Full Text
View/download PDF

24. Eating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome.

Author

Nguyen, Ngoc-Trang Adrienne, Yan Jiang, and McQuade, Jennifer L.

Subjects
DIETARY patterns, IMMUNOTHERAPY, DIET, GUT microbiome, INGESTION
Abstract

The gut microbiome (GMB) plays a substantial role in human health and disease. From affecting gut barrier integrity to promoting immune cell differentiation, the GMB is capable of shaping host immunity and thus oncogenesis and anti-cancer therapeutic response, particularly with immunotherapy. Dietary patterns and components are key determinants of GMB composition, supporting the investigation of the diet-microbiome-immunity axis as a potential avenue to enhance immunotherapy response in cancer patients. As such, this review will discuss the role of the GMB and diet on anti-cancer immunity. We demonstrate that diet affects anti-cancer immunity through both GMB-independent and GMB-mediated mechanisms, and that different diet patterns mold the GMB's functional and taxonomic composition in distinctive ways. Dietary modulation therefore shows promise as an intervention for improving cancer outcome; however, further and more extensive research in human cancer populations is needed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Data from Aerobic Exercise Alters the Melanoma Microenvironment and Modulates ERK5 S496 Phosphorylation

Author

Savage, Hannah, primary, Pareek, Sumedha, primary, Lee, Jonghae, primary, Ballarò, Riccardo, primary, Conterno Minussi, Darlan, primary, Hayek, Karma, primary, Sadullozoda, Mumina, primary, Lochmann, Brooke S., primary, McQuade, Jennifer L., primary, LaVoy, Emily C., primary, Marmonti, Enrica, primary, Patel, Hetal, primary, Wang, Guangyu, primary, Imanishi, Masaki, primary, Kotla, Sivareddy, primary, Abe, Jun-ichi, primary, and Schadler, Keri, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figures from Aerobic Exercise Alters the Melanoma Microenvironment and Modulates ERK5 S496 Phosphorylation

Author

Savage, Hannah, primary, Pareek, Sumedha, primary, Lee, Jonghae, primary, Ballarò, Riccardo, primary, Conterno Minussi, Darlan, primary, Hayek, Karma, primary, Sadullozoda, Mumina, primary, Lochmann, Brooke S., primary, McQuade, Jennifer L., primary, LaVoy, Emily C., primary, Marmonti, Enrica, primary, Patel, Hetal, primary, Wang, Guangyu, primary, Imanishi, Masaki, primary, Kotla, Sivareddy, primary, Abe, Jun-ichi, primary, and Schadler, Keri, primary

Published
2023
Full Text
View/download PDF

28. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection

Author

Tio, Martin, Rai, Rajat, Ezeoke, Ogochukwu M., McQuade, Jennifer L., Zimmer, Lisa, Khoo, Chloe, Park, John J., Spain, Lavinia, Turajlic, Samra, Ardolino, Luke, Yip, Desmond, Goldinger, Simone M., Cohen, Justine V., Millward, Michael, Atkinson, Victoria, Kane, Alisa Y., Ascierto, Paolo A., Garbe, Claus, Gutzmer, Ralf, Johnson, Douglas B., Rizvi, Hira A., Joshua, Anthony M., Hellmann, Matthew D., Long, Georgina V., and Menzies, Alexander M.

Published
2018
Full Text
View/download PDF

29. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Author

Amaria, Rodabe N, Prieto, Peter A, Tetzlaff, Michael T, Reuben, Alexandre, Andrews, Miles C, Ross, Merrick I, Glitza, Isabella C, Cormier, Janice, Hwu, Wen-Jen, Tawbi, Hussein A, Patel, Sapna P, Lee, Jeffrey E, Gershenwald, Jeffrey E, Spencer, Christine N, Gopalakrishnan, Vancheswaran, Bassett, Roland, Simpson, Lauren, Mouton, Rosalind, Hudgens, Courtney W, Zhao, Li, Zhu, Haifeng, Cooper, Zachary A, Wani, Khalida, Lazar, Alexander, Hwu, Patrick, Diab, Adi, Wong, Michael K, McQuade, Jennifer L, Royal, Richard, Lucci, Anthony, Burton, Elizabeth M, Reddy, Sangeetha, Sharma, Padmanee, Allison, James, Futreal, Phillip A, Woodman, Scott E, Davies, Michael A, and Wargo, Jennifer A

Published
2018
Full Text
View/download PDF

32. Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma

Author

Witt, Russell G., primary, Cass, Samuel H., additional, Tran, Tiffaney, additional, Damania, Ashish, additional, Nelson, Emelie E., additional, Sirmans, Elizabeth, additional, Burton, Elizabeth M., additional, Chelvanambi, Manoj, additional, Johnson, Sarah, additional, Tawbi, Hussein A., additional, Gershenwald, Jeffrey E., additional, Davies, Michael A., additional, Spencer, Christine, additional, Mishra, Aditya, additional, Wong, Matthew C., additional, Ajami, Nadim J., additional, Peterson, Christine B., additional, Daniel, Carrie R., additional, Wargo, Jennifer A., additional, McQuade, Jennifer L., additional, and Nelson, Kelly C., additional

Published
2023
Full Text
View/download PDF

34. Aerobic Exercise Alters the Melanoma Microenvironment and Modulates ERK5 S496 Phosphorylation

Author

Savage, Hannah, primary, Pareek, Sumedha, additional, Lee, Jonghae, additional, Ballarò, Riccardo, additional, Conterno Minussi, Darlan, additional, Hayek, Karma, additional, Sadullozoda, Mumina, additional, Lochmann, Brooke S., additional, McQuade, Jennifer L., additional, LaVoy, Emily C., additional, Marmonti, Enrica, additional, Patel, Hetal, additional, Wang, Guangyu, additional, Imanishi, Masaki, additional, Kotla, Sivareddy, additional, Abe, Jun-ichi, additional, and Schadler, Keri, additional

Published
2023
Full Text
View/download PDF

35. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer

Author

Leo, Javier, primary, Dondossola, Eleonora, additional, Basham, Kaitlin J, additional, Wilson, Nathaniel R, additional, Alhalabi, Omar, additional, Gao, Jianjun, additional, Kurnit, Katherine C, additional, White, Michael G, additional, McQuade, Jennifer L, additional, Westin, Shannon N, additional, Wellberg, Elizabeth A, additional, and Frigo, Daniel E, additional

Published
2023
Full Text
View/download PDF

36. Supplementary Tables from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

Author

Varghese, Sruthy, primary, Pramanik, Snigdha, primary, Williams, Leila J., primary, Hodges, Hannah R., primary, Hudgens, Courtney W., primary, Fischer, Grant M., primary, Luo, Catherine K., primary, Knighton, Barbara, primary, Tan, Lin, primary, Lorenzi, Philip L., primary, Mackinnon, Andrew L., primary, McQuade, Jennifer L., primary, Hailemichael, Yared, primary, Roszik, Jason, primary, Peng, Weiyi, primary, and Vashisht Gopal, Y.N., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figures from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

Author

Varghese, Sruthy, primary, Pramanik, Snigdha, primary, Williams, Leila J., primary, Hodges, Hannah R., primary, Hudgens, Courtney W., primary, Fischer, Grant M., primary, Luo, Catherine K., primary, Knighton, Barbara, primary, Tan, Lin, primary, Lorenzi, Philip L., primary, Mackinnon, Andrew L., primary, McQuade, Jennifer L., primary, Hailemichael, Yared, primary, Roszik, Jason, primary, Peng, Weiyi, primary, and Vashisht Gopal, Y.N., primary

Published
2023
Full Text
View/download PDF

38. Table S2 from Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases

Author

Fischer, Grant M., primary, Jalali, Ali, primary, Kircher, David A., primary, Lee, Won-Chul, primary, McQuade, Jennifer L., primary, Haydu, Lauren E., primary, Joon, Aron Y., primary, Reuben, Alexandre, primary, de Macedo, Mariana P., primary, Carapeto, Fernando C. L., primary, Yang, Chendong, primary, Srivastava, Anuj, primary, Ambati, Chandrashekar R., primary, Sreekumar, Arun, primary, Hudgens, Courtney W., primary, Knighton, Barbara, primary, Deng, Wanleng, primary, Ferguson, Sherise D., primary, Tawbi, Hussein A., primary, Glitza, Isabella C., primary, Gershenwald, Jeffrey E., primary, Vashisht Gopal, Y. N., primary, Hwu, Patrick, primary, Huse, Jason T., primary, Wargo, Jennifer A., primary, Futreal, P. Andrew, primary, Putluri, Nagireddy, primary, Lazar, Alexander J., primary, DeBerardinis, Ralph J., primary, Marszalek, Joseph R., primary, Zhang, Jianjun, primary, Holmen, Sheri L., primary, Tetzlaff, Michael T., primary, and Davies, Michael A., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Materials from Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases

Author

Fischer, Grant M., primary, Jalali, Ali, primary, Kircher, David A., primary, Lee, Won-Chul, primary, McQuade, Jennifer L., primary, Haydu, Lauren E., primary, Joon, Aron Y., primary, Reuben, Alexandre, primary, de Macedo, Mariana P., primary, Carapeto, Fernando C. L., primary, Yang, Chendong, primary, Srivastava, Anuj, primary, Ambati, Chandrashekar R., primary, Sreekumar, Arun, primary, Hudgens, Courtney W., primary, Knighton, Barbara, primary, Deng, Wanleng, primary, Ferguson, Sherise D., primary, Tawbi, Hussein A., primary, Glitza, Isabella C., primary, Gershenwald, Jeffrey E., primary, Vashisht Gopal, Y. N., primary, Hwu, Patrick, primary, Huse, Jason T., primary, Wargo, Jennifer A., primary, Futreal, P. Andrew, primary, Putluri, Nagireddy, primary, Lazar, Alexander J., primary, DeBerardinis, Ralph J., primary, Marszalek, Joseph R., primary, Zhang, Jianjun, primary, Holmen, Sheri L., primary, Tetzlaff, Michael T., primary, and Davies, Michael A., primary

Published
2023
Full Text
View/download PDF

40. Supplemental Figures from Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases

Author

Fischer, Grant M., primary, Jalali, Ali, primary, Kircher, David A., primary, Lee, Won-Chul, primary, McQuade, Jennifer L., primary, Haydu, Lauren E., primary, Joon, Aron Y., primary, Reuben, Alexandre, primary, de Macedo, Mariana P., primary, Carapeto, Fernando C. L., primary, Yang, Chendong, primary, Srivastava, Anuj, primary, Ambati, Chandrashekar R., primary, Sreekumar, Arun, primary, Hudgens, Courtney W., primary, Knighton, Barbara, primary, Deng, Wanleng, primary, Ferguson, Sherise D., primary, Tawbi, Hussein A., primary, Glitza, Isabella C., primary, Gershenwald, Jeffrey E., primary, Vashisht Gopal, Y. N., primary, Hwu, Patrick, primary, Huse, Jason T., primary, Wargo, Jennifer A., primary, Futreal, P. Andrew, primary, Putluri, Nagireddy, primary, Lazar, Alexander J., primary, DeBerardinis, Ralph J., primary, Marszalek, Joseph R., primary, Zhang, Jianjun, primary, Holmen, Sheri L., primary, Tetzlaff, Michael T., primary, and Davies, Michael A., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figures from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

Author

Romano, Gabriele, primary, Chen, Pei-Ling, primary, Song, Ping, primary, McQuade, Jennifer L., primary, Liang, Roger J., primary, Liu, Mingguang, primary, Roh, Whijae, primary, Duose, Dzifa Y., primary, Carapeto, Fernando C.L., primary, Li, Jun, primary, Teh, Jessica L.F., primary, Aplin, Andrew E., primary, Chen, Merry, primary, Zhang, Jianhua, primary, Lazar, Alexander J., primary, Davies, Michael A., primary, Futreal, P. Andrew, primary, Amaria, Rodabe N., primary, Zhang, David Y., primary, Wargo, Jennifer A., primary, and Kwong, Lawrence N., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Tables from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

Author

Romano, Gabriele, primary, Chen, Pei-Ling, primary, Song, Ping, primary, McQuade, Jennifer L., primary, Liang, Roger J., primary, Liu, Mingguang, primary, Roh, Whijae, primary, Duose, Dzifa Y., primary, Carapeto, Fernando C.L., primary, Li, Jun, primary, Teh, Jessica L.F., primary, Aplin, Andrew E., primary, Chen, Merry, primary, Zhang, Jianhua, primary, Lazar, Alexander J., primary, Davies, Michael A., primary, Futreal, P. Andrew, primary, Amaria, Rodabe N., primary, Zhang, David Y., primary, Wargo, Jennifer A., primary, and Kwong, Lawrence N., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Author

Peng, Weiyi, primary, Chen, Jie Qing, primary, Liu, Chengwen, primary, Malu, Shruti, primary, Creasy, Caitlin, primary, Tetzlaff, Michael T., primary, Xu, Chunyu, primary, McKenzie, Jodi A., primary, Zhang, Chunlei, primary, Liang, Xiaoxuan, primary, Williams, Leila J., primary, Deng, Wanleng, primary, Chen, Guo, primary, Mbofung, Rina, primary, Lazar, Alexander J., primary, Torres-Cabala, Carlos A., primary, Cooper, Zachary A., primary, Chen, Pei-Ling, primary, Tieu, Trang N., primary, Spranger, Stefani, primary, Yu, Xiaoxing, primary, Bernatchez, Chantale, primary, Forget, Marie-Andree, primary, Haymaker, Cara, primary, Amaria, Rodabe, primary, McQuade, Jennifer L., primary, Glitza, Isabella C., primary, Cascone, Tina, primary, Li, Haiyan S., primary, Kwong, Lawrence N., primary, Heffernan, Timothy P., primary, Hu, Jianhua, primary, Bassett, Roland L., primary, Bosenberg, Marcus W., primary, Woodman, Scott E., primary, Overwijk, Willem W., primary, Lizée, Gregory, primary, Roszik, Jason, primary, Gajewski, Thomas F., primary, Wargo, Jennifer A., primary, Gershenwald, Jeffrey E., primary, Radvanyi, Laszlo, primary, Davies, Michael A., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure S7 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Author

Peng, Weiyi, primary, Chen, Jie Qing, primary, Liu, Chengwen, primary, Malu, Shruti, primary, Creasy, Caitlin, primary, Tetzlaff, Michael T., primary, Xu, Chunyu, primary, McKenzie, Jodi A., primary, Zhang, Chunlei, primary, Liang, Xiaoxuan, primary, Williams, Leila J., primary, Deng, Wanleng, primary, Chen, Guo, primary, Mbofung, Rina, primary, Lazar, Alexander J., primary, Torres-Cabala, Carlos A., primary, Cooper, Zachary A., primary, Chen, Pei-Ling, primary, Tieu, Trang N., primary, Spranger, Stefani, primary, Yu, Xiaoxing, primary, Bernatchez, Chantale, primary, Forget, Marie-Andree, primary, Haymaker, Cara, primary, Amaria, Rodabe, primary, McQuade, Jennifer L., primary, Glitza, Isabella C., primary, Cascone, Tina, primary, Li, Haiyan S., primary, Kwong, Lawrence N., primary, Heffernan, Timothy P., primary, Hu, Jianhua, primary, Bassett, Roland L., primary, Bosenberg, Marcus W., primary, Woodman, Scott E., primary, Overwijk, Willem W., primary, Lizée, Gregory, primary, Roszik, Jason, primary, Gajewski, Thomas F., primary, Wargo, Jennifer A., primary, Gershenwald, Jeffrey E., primary, Radvanyi, Laszlo, primary, Davies, Michael A., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Methods from The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies

Author

Varghese, Sruthy, primary, Pramanik, Snigdha, primary, Williams, Leila J., primary, Hodges, Hannah R., primary, Hudgens, Courtney W., primary, Fischer, Grant M., primary, Luo, Catherine K., primary, Knighton, Barbara, primary, Tan, Lin, primary, Lorenzi, Philip L., primary, Mackinnon, Andrew L., primary, McQuade, Jennifer L., primary, Hailemichael, Yared, primary, Roszik, Jason, primary, Peng, Weiyi, primary, and Vashisht Gopal, Y.N., primary

Published
2023
Full Text
View/download PDF

46. Data from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

Author

Romano, Gabriele, primary, Chen, Pei-Ling, primary, Song, Ping, primary, McQuade, Jennifer L., primary, Liang, Roger J., primary, Liu, Mingguang, primary, Roh, Whijae, primary, Duose, Dzifa Y., primary, Carapeto, Fernando C.L., primary, Li, Jun, primary, Teh, Jessica L.F., primary, Aplin, Andrew E., primary, Chen, Merry, primary, Zhang, Jianhua, primary, Lazar, Alexander J., primary, Davies, Michael A., primary, Futreal, P. Andrew, primary, Amaria, Rodabe N., primary, Zhang, David Y., primary, Wargo, Jennifer A., primary, and Kwong, Lawrence N., primary

Published
2023
Full Text
View/download PDF

47. Data from Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases

Author

Fischer, Grant M., primary, Jalali, Ali, primary, Kircher, David A., primary, Lee, Won-Chul, primary, McQuade, Jennifer L., primary, Haydu, Lauren E., primary, Joon, Aron Y., primary, Reuben, Alexandre, primary, de Macedo, Mariana P., primary, Carapeto, Fernando C. L., primary, Yang, Chendong, primary, Srivastava, Anuj, primary, Ambati, Chandrashekar R., primary, Sreekumar, Arun, primary, Hudgens, Courtney W., primary, Knighton, Barbara, primary, Deng, Wanleng, primary, Ferguson, Sherise D., primary, Tawbi, Hussein A., primary, Glitza, Isabella C., primary, Gershenwald, Jeffrey E., primary, Vashisht Gopal, Y. N., primary, Hwu, Patrick, primary, Huse, Jason T., primary, Wargo, Jennifer A., primary, Futreal, P. Andrew, primary, Putluri, Nagireddy, primary, Lazar, Alexander J., primary, DeBerardinis, Ralph J., primary, Marszalek, Joseph R., primary, Zhang, Jianjun, primary, Holmen, Sheri L., primary, Tetzlaff, Michael T., primary, and Davies, Michael A., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure Legends from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling

Author

Romano, Gabriele, primary, Chen, Pei-Ling, primary, Song, Ping, primary, McQuade, Jennifer L., primary, Liang, Roger J., primary, Liu, Mingguang, primary, Roh, Whijae, primary, Duose, Dzifa Y., primary, Carapeto, Fernando C.L., primary, Li, Jun, primary, Teh, Jessica L.F., primary, Aplin, Andrew E., primary, Chen, Merry, primary, Zhang, Jianhua, primary, Lazar, Alexander J., primary, Davies, Michael A., primary, Futreal, P. Andrew, primary, Amaria, Rodabe N., primary, Zhang, David Y., primary, Wargo, Jennifer A., primary, and Kwong, Lawrence N., primary

Published
2023
Full Text
View/download PDF

49. Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

Author

Peng, Weiyi, primary, Chen, Jie Qing, primary, Liu, Chengwen, primary, Malu, Shruti, primary, Creasy, Caitlin, primary, Tetzlaff, Michael T., primary, Xu, Chunyu, primary, McKenzie, Jodi A., primary, Zhang, Chunlei, primary, Liang, Xiaoxuan, primary, Williams, Leila J., primary, Deng, Wanleng, primary, Chen, Guo, primary, Mbofung, Rina, primary, Lazar, Alexander J., primary, Torres-Cabala, Carlos A., primary, Cooper, Zachary A., primary, Chen, Pei-Ling, primary, Tieu, Trang N., primary, Spranger, Stefani, primary, Yu, Xiaoxing, primary, Bernatchez, Chantale, primary, Forget, Marie-Andree, primary, Haymaker, Cara, primary, Amaria, Rodabe, primary, McQuade, Jennifer L., primary, Glitza, Isabella C., primary, Cascone, Tina, primary, Li, Haiyan S., primary, Kwong, Lawrence N., primary, Heffernan, Timothy P., primary, Hu, Jianhua, primary, Bassett, Roland L., primary, Bosenberg, Marcus W., primary, Woodman, Scott E., primary, Overwijk, Willem W., primary, Lizée, Gregory, primary, Roszik, Jason, primary, Gajewski, Thomas F., primary, Wargo, Jennifer A., primary, Gershenwald, Jeffrey E., primary, Radvanyi, Laszlo, primary, Davies, Michael A., primary, and Hwu, Patrick, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Tables 1 and 6-8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma

Author

Hahn, Andrew W., primary, Menk, Ashley V., primary, Rivadeneira, Dayana B., primary, Augustin, Ryan C., primary, Xu, Mingchu, primary, Li, Jun, primary, Wu, Xiaogang, primary, Mishra, Aditya K., primary, Gide, Tuba N., primary, Quek, Camelia, primary, Zang, Yan, primary, Spencer, Christine N., primary, Menzies, Alexander M., primary, Daniel, Carrie R., primary, Hudgens, Courtney W., primary, Nowicki, Theodore, primary, Haydu, Lauren E., primary, Khan, M.A. Wadud, primary, Gopalakrishnan, Vancheswaran, primary, Burton, Elizabeth M., primary, Malke, Jared, primary, Simon, Julie M., primary, Bernatchez, Chantale, primary, Putluri, Nagireddy, primary, Woodman, Scott E., primary, Vashisht Gopal, Y.N., primary, Guerrieri, Renato, primary, Fischer, Grant M., primary, Wang, Jian, primary, Wani, Khalida M., primary, Thompson, John F., primary, Lee, Jeffrey E., primary, Hwu, Patrick, primary, Ajami, Nadim, primary, Gershenwald, Jeffrey E., primary, Long, Georgina V., primary, Scolyer, Richard A., primary, Tetzlaff, Michael T., primary, Lazar, Alexander J., primary, Schadendorf, Dirk, primary, Wargo, Jennifer A., primary, Kirkwood, John M., primary, DeBerardinis, Ralph J., primary, Liang, Han, primary, Futreal, Andrew, primary, Zhang, Jianhua, primary, Wilmott, James S., primary, Peng, Weiyi, primary, Davies, Michael A., primary, Delgoffe, Greg M., primary, Najjar, Yana G., primary, and McQuade, Jennifer L., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results